Title:
NOVEL CANNABIDIOL DERIVATIVE, METHOD FOR PREPARING SAME, AND COMPOSITION FOR COGNITIVE FUNCTION IMPROVEMENT COMPRISING SAME
Document Type and Number:
WIPO Patent Application WO/2023/043197
Kind Code:
A1
Abstract:
The present invention provides a cannabidiol derivative, a method for preparing same, and a composition for cognitive function improvement comprising same. The novel cannabidiol derivative of the present invention has been confirmed to exhibit not only acetylcholinesterase inhibitory efficacy and butyrylcholinesterase inhibitory efficacy but also efficacy in inhibiting monoamine oxidase B, so that the reduction in the level of acetylcholine in brain tissues and the reduction in the level of butyrylcholine in the blood, which appear in patients with dementia, can be simultaneously achieved and, by preventing brain cell damage, more effective cognitive-function improvement and treatment effects can be expected. Therefore, the cannabidiol derivative, the method for preparing same, and the composition for improving cognitive function comprising same, of the present invention, can be usefully used as a substance for improving cognitive function in the medicinal and health functional food fields as a cognitive-function improving substance, which is a substance that simultaneously inhibits acetylcholinesterase, butyrylcholinesterase, and monoamine oxidase B.
Inventors:
LEE KOO YEON (KR)
Application Number:
PCT/KR2022/013736
Publication Date:
March 23, 2023
Filing Date:
September 14, 2022
Export Citation:
Assignee:
KANGWON UNIV INDUSTRY COOPERATION FOUNDATION (KR)
International Classes:
C07C39/23; C07C39/373; C07C43/23; C07C205/16; C07C245/08; C07C255/33; C07C311/29; C07C323/16; C07C323/18; C07C329/06
Domestic Patent References:
| WO2011006099A1 | 2011-01-13 | |||
| WO2016138383A1 | 2016-09-01 | |||
| WO2017178810A1 | 2017-10-19 |
Foreign References:
| KR20210090609A | 2021-07-20 |
Other References:
WRÓBEL ANDRZEJ, SEREFKO ANNA, SZOPA ALEKSANDRA, ULRICH DANIELA, POLESZAK EWA, RECHBERGER TOMASZ: "O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment", FRONTIERS IN PHARMACOLOGY, vol. 11, XP093047682, DOI: 10.3389/fphar.2020.01002
Attorney, Agent or Firm:
PHIL & ONZI INT'L PATENT & LAW FIRM (KR)
Download PDF: